press release

5.5.14

Epic Sciences selected to present at Cavendish Global Health Impact Forum.

Forum uniquely brings together leading family offices and their foundations seeking impact investment, grand-giving and philanthropy oportunities within health and science.

Epic Sciences, developer of novel diagnostics to personalize and advance the treatment and management of cancer, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place May 5-7 New York, NY. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences.

To accomplish this mission the Forum showcases presentations and panel discussions by leading scientists, accomplished healthcare delivery professionals, health-policy experts and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment.

Michael Moffat, Cavendish co-founder and president explains, "With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of Epic Sciences's research and scientific insights in circulating tumor cells positions them to make a major contribution to deliver precision medicine for cancer treatment and management."

"We are honored to be selected to present at this unique event, and it is further recognition of our innovative approach to the rapid and non-invasive detection of genetic and molecular changes in cancer that can help match patients to targeted therapies and monitor for drug resistance across a broad spectrum of cancers afflicting populations around the world today," said Murali Prahalad, Ph.D., president and CEO of Epic Sciences. "We welcome the chance to interact with many of world's leading scientific minds, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world."

Cavendish Global consists of over 150 leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world. Cavendish Global together with the Global Partnerships Forum and the New York Academy of Sciences organizes the Forum annually in New York.

About Cavendish Global

Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment, grant making and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, which includes Cavendish Impact Forums. A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; in the United States (taking place in New York at the United Nations Headquarters May 5th to 7th 2014), Europe (UK, November 2014, in association with SV Life Sciences, hosted by Oxford University) and a third event held at a Cavendish Host Partner City which moves to a different global location each year (Dubai, UAE January 2015).

About Epic Sciences

At Epic Sciences, we develop clinically proven predictive tests to detect and monitor cancer at the individual cell level. With a proprietary rare-cell detection engine, we provide insights to clinical, biotech, pharmaceutical and academic teams on how cancer emerges, mutates and remits so they can make pivotal decisions at every point in patient treatment with greater certainty. Recognizing the unique nature of each person’s cancer, we offer truly personalized diagnostic tests, while being non-invasive for the patient.

We have developed the first clinically proven predictive test for metastatic castration-resistant prostrate cancer (mCRPC), the Epic AR-V7 test. Using the same rare-cell detection platform and Epic’s biobank of over 30,000 blood samples, each profiled with predictive biomarkers, we partner with leading pharmaceutical and biotechnology companies, major cancer centers, the National Cancer Institute (NCI), and the National Institutes of Health (NIH) to pursue additional predictive tests for breast, ovarian, colon and other cancers and diseases. Our mission is to revolutionize cancer care and therapies to make them as precise, safe and life-sustaining as humanly possible.

For more information, visit epicsciences.com.

Stay in touch on LinkedIn, on Twitter@EpicSciences and Facebook.com/EpicSciences.

Epic Sciences Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com,+1.858.344.8091